Literature DB >> 9636210

The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop.

T M Ross1, B R Cullen.   

Abstract

Although infection by primary HIV type 1 (HIV-1) isolates normally requires the functional interaction of the viral envelope protein with both CD4 and the CCR-5 coreceptor, a subset of such isolates also are able to use the distinct CCR-3 receptor. By analyzing the ability of a series of wild-type and chimeric HIV-1 envelope proteins to mediate CCR-3-dependent infection, we have determined that CCR-3 tropism maps to the V1 and V2 variable region of envelope. Although substitution of the V1/V2 region of a CCR-3 tropic envelope into the context of a CCR-5 tropic envelope is both necessary and sufficient to confer CCR-3 tropism, this same substitution has no phenotypic effect when inserted into a CXCR-4 tropic HIV-1 envelope context. However, this latter chimera acquires both CCR-3 and CCR-5 tropism when a CCR-5 tropic V3 loop sequence also is introduced. These data demonstrate that the V1/2 region of envelope can, like the V3 loop region, encode a particular coreceptor requirement and suggest that a functional envelope:CCR-3 interaction may depend on the cooperative interaction of CCR-3 with both the V1/V2 and the V3 region of envelope.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636210      PMCID: PMC22722          DOI: 10.1073/pnas.95.13.7682

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry.

Authors:  R W Doms; S C Peiper
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

2.  Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.

Authors:  F Sallusto; C R Mackay; A Lanzavecchia
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

3.  HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor.

Authors:  P D Bieniasz; R A Fridell; I Aramori; S S Ferguson; M G Caron; B R Cullen
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

4.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.

Authors:  J Rucker; A L Edinger; M Sharron; M Samson; B Lee; J F Berson; Y Yi; B Margulies; R G Collman; B J Doranz; M Parmentier; R W Doms
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.

Authors:  J Cao; N Sullivan; E Desjardin; C Parolin; J Robinson; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.

Authors:  M W Cho; M K Lee; M C Carney; J F Berson; R W Doms; M A Martin
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 7.  Co-receptors for HIV-1 entry.

Authors:  J P Moore; A Trkola; T Dragic
Journal:  Curr Opin Immunol       Date:  1997-08       Impact factor: 7.486

8.  Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop.

Authors:  R F Speck; K Wehrly; E J Platt; R E Atchison; I F Charo; D Kabat; B Chesebro; M A Goldsmith
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.

Authors:  B J Doranz; Z H Lu; J Rucker; T Y Zhang; M Sharron; Y H Cen; Z X Wang; H H Guo; J G Du; M A Accavitti; R W Doms; S C Peiper
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  42 in total

1.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.

Authors:  T L Hoffman; C C LaBranche; W Zhang; G Canziani; J Robinson; I Chaiken; J A Hoxie; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

4.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure.

Authors:  Shang-Rung Wu; Robin Löving; Birgitta Lindqvist; Hans Hebert; Philip J B Koeck; Mathilda Sjöberg; Henrik Garoff
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

7.  The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

Authors:  Abraham Pinter; William J Honnen; Paul D'Agostino; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

9.  Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.

Authors:  K Tokunaga; M L Greenberg; M A Morse; R I Cumming; H K Lyerly; B R Cullen
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

10.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.